Pharmacological treatment for psychotic depression

Jaap Wijkstra; Jeroen Lijmer; Ferdi Balk; John Geddes; Willem A Nolen

doi:10.1002/14651858.CD004044.pub2

Cochrane Database of Systematic Reviews

Pharmacological treatment for psychotic depression

Información

DOI:

https://doi.org/10.1002/14651858.CD004044.pub2 Copiar DOI

Base de datos:

Cochrane Database of Systematic Reviews

Versión publicada:

19 octubre 2005see what's new

Tipo:

Intervention

Etapa:

Review

Grupo Editorial Cochrane:

Grupo Cochrane de Trastornos mentales comunes

Copyright:

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

Jaap Wijkstra

Correspondencia a: Psychiatry, UMCU, Utrecht, Netherlands

[email protected]
Jeroen Lijmer

Psychiatry, UMCU, Utrecht, Netherlands
Ferdi Balk

Psychiatry, Medical Centre Haaglanden, The Hague, Netherlands
John Geddes

Department of Psychiatry, University of Oxford, Oxford, UK
Willem A Nolen

Department of Psychiatry, University Hospital Groningen, Groningen, Netherlands

Contributions of authors

J Wijkstra: Development of protocol, coordinating and writing the review, data collection, analysis, primary author report.
J Lijmer: Development of protocol, data collection, analysis, co‐author report.
F Balk: Data collection, co‐author report
J Geddes: External reviewer, co‐author report.
WA Nolen: Development of protocol, data collection, analysis, overall supervision, co‐author report.

Sources of support

Internal sources

No sources of support supplied

External sources

Wyeth, Netherlands.
AstraZeneca, Netherlands.

Declarations of interest

JW and WN are currently conducting a multi‐centre trial in patients with psychotic depression comparing treatment with imipramine, venlafaxine and venlafaxine plus quetiapine. Wyeth and AstraZeneca are financially supporting this trial. They also supported financially the literature search for this review. JG has received research funding and support from Sanofi‐Aventis and GlaxoSmithKline and is currently in discussion with several other companies that manufacture SSRIs about collaboration on planned independent trials and systematic reviews.

The pharmaceutical company's (AstraZeneca and Wyeth) involvement was two 2500 Euro donations, so we could pay someone (a medical student) searching the literature, downloading articles, and screening the articles. There was absolutely no restriction. Until now they have not seen the review.

Acknowledgements

We would like to thank Dr J. Bruijn, Dr W.W. van den Broek and Dr. R. Zanardi for giving additional information about their studies.

Version history

Published

Title

Stage

Authors

Version

2021 Dec 07